Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure
Alberto Ortíz(Universidad Pontificia de Salamanca), Gérard M. London(Unknown), Andrzej Więcek(Medical University of Silesia), David Goldsmith(University College London), Carmine Zoccali(Biogem), R. Vanholder(Ghent University Hospital), Ziad A. Massy(Inserm), Patrick Rossignol(Inserm), Adrian Covic(Grigore T. Popa University of Medicine and Pharmacy), Danilo Fliser(Saarland University), Denis Fouque(Université Claude Bernard Lyon 1), Francesca Mallamaci(Ospedali Riuniti di Foggia), Mehmet Kanbay(Koç University)
Cited by 433
Related Papers
Obesity and Kidney Disease: Hidden Consequences of the Epidemic
|American Journal of Nephrology|2017|2.2k
Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study
|The Lancet|2001|1.1k
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
|The Lancet|2017|923
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
|The Lancet|1999|909
A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases
|Kidney International|2019|886